Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in children aged 6 to under 12 years with moderate to severe plaque psoriasis
NL-OMON45724Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ustekinumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoints: Physician's Global Assessment, Psoriasis Area and Severity Index and 2 more. Started Jul 2017; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON45724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45724.